Logo

Urovant's Vibegron Fails to Meet its Primary Endpoint in P-IIa Study for IBS Pain

Share this

Urovant's Vibegron Fails to Meet its Primary Endpoint in P-IIa Study for IBS Pain

Shots:

  • The P-IIa study involves assessing vibegron (75mg-qd) in 222 women with abdominal pain due to IBS with IBS-D (diarrhea) and IBS-M (mixed IBS) across 35 sites in the US
  • The study did not meet its 1EPs i.e. at least a 30 percent improvement in average worst abdominal pain @12wks. ( 40.9% vs 42.9%)- well tolerated and did not lead to worsening of IBS symptoms
  • Vibegron is (PO-qd) is a beta-3 agonist that is being evaluated for OAB- OAB+BPH in men & for abdominal pain associated with IBS

 ­ Ref: Businesswire | Image: Urovant

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions